Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18402676 | 0.81 | TRIM24 (0.33) | TRIM24TRIM33ESR2ALDH1A1 | |
| SCHEMBL7877671 | 0.78 | TRIM24 (0.35) | TRIM24TRIM33ESR2ALDH1A1 | |
| SCHEMBL21598367 | 0.77 | ESR2 (0.30) | ESR2 | |
| SCHEMBL1965395 | 0.76 | — | — | |
| SCHEMBL26343884 | 0.75 | MMP1 (0.31) | — | |
| SCHEMBL10018103 | 0.74 | LMNA (0.48) | TRIM24TRIM33ESR2ALDH1A1 | |
| SCHEMBL21826881 | 0.74 | APLNR (0.37) | TRIM24TRIM33ESR2ALDH1A1 | |
| SCHEMBL16052074 | 0.74 | TRIM24 (0.32) | TRIM24TRIM33ESR2ALDH1A1 | |
| SCHEMBL21194381 | 0.72 | — | — | |
| SCHEMBL21598356 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389561-B2 | Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions | UNIVERSITEIT GENT (BE) | 2013-03-05 | — | — | US | claimed |
| US-7884125-B2 | 7-benzyl-7-azabicyclo[2.2.1]hept-1-ylmethyl)-pyridin-2-yl-amine, used for the treatment of diseases mediated by Nicotinic Acetylcholine Receptors, such as pain, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy and drug addiction | UNIVERSITEIT GENT (BE) | 2011-02-08 | — | — | US | claimed |
| US-20100093807-A1 | SUBSTITUTED 7-AZABICYCLO[2.2.1]HEPTYL DERIVATIVES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2010-04-15 | — | — | US | claimed |
| US-20090275616-A1 | STRAIGHTFORWARD ENTRY TO 7-AZABICYCLO[2.2.1]HEPTANE-1-CARBONITRILES AND SUBSEQUENT SYNTHESIS OF EPIBATIDINE ANALOGUES | UNIVERSITEIT GENT (BE) | 2009-11-05 | — | — | US | claimed |
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-4596544-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Miracure Biotechnology Limited (CN) | 2025-08-06 | — | — | EP | disclosed |
| CN-119241481-A | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2024-11-21 | — | — | US | disclosed |
| CN-115298170-B | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| US-11976073-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240109868-A1 | EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Miracure Biotechnology Limited (CN) | 2024-04-04 | — | — | US | disclosed |
| US-7884125-B2 | 7-benzyl-7-azabicyclo[2.2.1]hept-1-ylmethyl)-pyridin-2-yl-amine, used for the treatment of diseases mediated by Nicotinic Acetylcholine Receptors, such as pain, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy and drug addiction | UNIVERSITEIT GENT (BE) | 2011-02-08 | — | — | US | disclosed |
| US-20100093807-A1 | SUBSTITUTED 7-AZABICYCLO[2.2.1]HEPTYL DERIVATIVES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2010-04-15 | — | — | US | disclosed |
| EP-1709023-B1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275616-A1 | STRAIGHTFORWARD ENTRY TO 7-AZABICYCLO[2.2.1]HEPTANE-1-CARBONITRILES AND SUBSEQUENT SYNTHESIS OF EPIBATIDINE ANALOGUES | UNIVERSITEIT GENT (BE) | 2009-11-05 | — | — | US | disclosed |
| US-20070066595-A1 | Selective estrogen receptor modulators | ARRAY BIOPHARMA, INC. | 2007-03-22 | — | — | US | disclosed |
| EP-1709023-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073206-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066595-A1 | Selective estrogen receptor modulators | GPER1, ESR2, ESR1 | TRIM24 2026/4885TRIM33 3192/4885ESR2 2/4885 |
| US-20240109868-A1 | EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | EP300, CREBBP, BPTF | TRIM24 400/4885TRIM33 1305/4885ESR2 860/4885 |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | YAP1, TEAD3, TEAD2 | TRIM24 1999/4885TRIM33 1870/4885ESR2 3418/4885 |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | TRIM24 1999/4885TRIM33 1870/4885ESR2 3418/4885 |
| US-11976073-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CCNI, CDK1 | TRIM24 4018/4885TRIM33 4132/4885ESR2 1163/4885 |
| US-20100093807-A1 | SUBSTITUTED 7-AZABICYCLO[2.2.1]HEPTYL DERIVATIVES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS | CHRNA7, CHRNA5, CHRNA6 | TRIM24 4108/4885TRIM33 2349/4885ESR2 396/4885 |
| US-20090275616-A1 | STRAIGHTFORWARD ENTRY TO 7-AZABICYCLO[2.2.1]HEPTANE-1-CARBONITRILES AND SUBSEQUENT SYNTHESIS OF EPIBATIDINE ANALOGUES | CHRNA5, CHRNA7, CHRNA2 | TRIM24 4536/4885TRIM33 4548/4885ESR2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.